Another promising approach for hard-to-treat blood cancers
For patients with some hard-to-treat blood cancers, a simple “off-the-shelf” immunotherapy is achieving promising results. A clinical trial of the developmental drug Glofitamab has shown it can produce a durable “complete response”—meaning the cancer became undetectable—in patients with relapsed or treatment resistant B-cell lymphomas. One option for these patients is CAR T-cell therapy—also an immunotherapy but one which involves collecting […]
» Read more
